Iovance Biotherapeutics, Inc. $IOVA Stock Position Raised by Mirador Capital Partners LP

Key Points

• Mirador Capital Partners LP more than doubled its stake in Iovance in Q4 (up 100.9%), buying 519,519 shares to hold 1,034,544 shares—about 0.26% of the company—worth roughly $2.82 million.
• Iovance beat quarterly expectations (EPS of -$0.18 vs. -$0.22 est.; revenue $86.77M vs. $81.61M est.) but remains unprofitable with negative return on equity and net margin.
• Analysts are mixed: the consensus rating is "Hold" with an average price target of $8.88, while individual reports range from Buy to Sell (six Buys, four Holds, two Sells) and several recent price-target moves.

Mirador Capital Partners LP grew its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 100.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,034,544 shares of the biotechnology company's stock after buying an additional 519,519 shares during the quarter. Mirador Capital Partners LP owned approximately 0.26% of Iovance Biotherapeutics worth $2,824,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. Vontobel Holding Ltd. bought a new position in Iovance Biotherapeutics during the third quarter valued at approximately $26,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Iovance Biotherapeutics in the third quarter valued at approximately $27,000. Federated Hermes Inc. grew its position in Iovance Biotherapeutics by 67.6% in the third quarter. Federated Hermes Inc. now owns 15,111 shares of the biotechnology company's stock worth $33,000 after acquiring an additional 6,095 shares in the last quarter. Wealthfront Advisers LLC bought a new stake in Iovance Biotherapeutics in the third quarter worth approximately $34,000. Finally, R Squared Ltd increased its stake in shares of Iovance Biotherapeutics by 41.4% during the 3rd quarter. R Squared Ltd now owns 16,043 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 4,700 shares during the last quarter. Institutional investors own 77.03% of the company's stock.

Analyst Upgrades and Downgrades

IOVA has been the topic of a number of recent research reports. Citizens Jmp upgraded shares of Iovance Biotherapeutics from a "market perform" rating to a "market outperform" rating and set a $5.00 price target on the stock in a report on Tuesday, March 3rd. Barclays increased their target price on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 25th. Wall Street Zen upgraded Iovance Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. UBS Group boosted their price target on Iovance Biotherapeutics from $2.00 to $4.00 and gave the stock a "neutral" rating in a research report on Thursday, March 5th. Finally, Chardan Capital decreased their price target on Iovance Biotherapeutics from $17.00 to $16.00 and set a "buy" rating for the company in a research note on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Iovance Biotherapeutics presently has a consensus rating of "Hold" and an average price target of $8.88.

Iovance Biotherapeutics Stock Performance

NASDAQ IOVA opened at $3.51 on Friday. The stock has a 50-day simple moving average of $3.32 and a 200 day simple moving average of $2.67. Iovance Biotherapeutics, Inc. has a twelve month low of $1.64 and a twelve month high of $5.63. The stock has a market capitalization of $1.45 billion, a PE ratio of -3.13 and a beta of 0.69.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last released its earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.04. Iovance Biotherapeutics had a negative return on equity of 54.54% and a negative net margin of 148.41%.The firm had revenue of $86.77 million for the quarter, compared to analyst estimates of $81.61 million. As a group, equities research analysts forecast that Iovance Biotherapeutics, Inc. will post -1.24 EPS for the current fiscal year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company's lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance's pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance's TIL platform harnesses a patient's own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.